Press Release - November 26, 2024 Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Press Release - November 19, 2024 Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Press Release - October 15, 2024 Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth
September 17, 2024 Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
April 18, 2024 Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
January 4, 2024 Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
March 28, 2023 Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
January 9, 2023 Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
August 2, 2022 Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
June 13, 2022 Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
May 2, 2022 Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
April 11, 2022 Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
March 15, 2022 Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
March 15, 2022 Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
December 14, 2021 Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
September 21, 2021 Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
August 12, 2021 Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
August 3, 2021 Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
